AstraZeneca to share latest data from an industry-leading portfolio that aims to advance clinical understanding of diabetes and CV risk management at ADA 2018
Pressmeddelanden • Jun 19, 2018 08:02 CEST
Key data evaluating the efficacy and safety of Farxiga (dapagliflozin) in combination with other type-2 diabetes therapies head-to-head vs. insulin or sulfonylurea Latest data from the DEPICT clinical programme evaluating Farxiga to address an unmet need for oral therapy in adult patients with type-1 diabetes
Pressmeddelanden • Jun 12, 2018 08:03 CEST
Independent data monitoring committee advises lanabecestat is unlikely to meet primary endpoints, leading to decision to discontinue these trials
Pressmeddelanden • Jun 09, 2018 08:15 CEST
Today the European Commission has granted marketing authorisation for Tagrisso as monotherapy for the 1st-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. The approval is based on results from the Phase III FLAURA trial published in the New England Journal of Medicine.
Lynparza in combination with abiraterone delayed disease progression in metastatic castration-resistant prostate cancer
Pressmeddelanden • Jun 05, 2018 08:00 CEST
AstraZeneca and Merck today presented data, which showed clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care, in metastatic castration-resistant prostate cancer (mCRPC). Lynparza is being jointly developed and commercialised by AstraZeneca and MSD.
Moxetumomab pasudotox pivotal data in patients with previously-treated hairy cell leukaemia presented at the 2018 ASCO meeting
Pressmeddelanden • Jun 03, 2018 08:39 CEST
Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence of any remaining detectable cancer cells Phase III clinical trial results served as basis for recent US FDA regulatory submission
Pressmeddelanden • Maj 30, 2018 08:04 CEST
TERRANOVA trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with chronic obstructive pulmonary disease
Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer
Pressmeddelanden • Maj 25, 2018 08:02 CEST
AstraZeneca and MedImmune today announced positive overall survival results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled, multi-centre trial of Imfinzi in patients with unresectable Stage III non-small cell lung cancer whose disease had not progressed following platinum-based chemotherapy concurrent with radiation therapy.
AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline
Pressmeddelanden • Maj 24, 2018 08:02 CEST
AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 1-5 June 2018, with an expanded portfolio in Oncology.
Pressmeddelanden • Maj 21, 2018 08:07 CEST
AstraZeneca has submitted a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Forxiga (dapagliflozin), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).
Pressmeddelanden • Maj 18, 2018 23:40 CEST
The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults with hyperkalaemia,a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.
Pressmeddelanden • Maj 18, 2018 08:03 CEST
Bra lanseringar och resultat för våra nyare läkemedel stödjer oförändrad prognos
New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy ‘as needed’ in mild asthma
Pressmeddelanden • Maj 17, 2018 16:49 CEST
AstraZeneca today announced results from the Phase III SYGMA trials of Symbicort Turbuhaler (budesonide/formoterol) given as an anti-inflammatory reliever ‘as needed’ versus two different treatment regimens in patients with mild asthma.
AstraZeneca is advancing clinical practice in respiratory medicine with new data at the American Thoracic Society 2018 International Congress
Pressmeddelanden • Maj 16, 2018 08:05 CEST
AstraZeneca and MedImmune, its global biologics research and development arm, will present updates from its respiratory medicines and pipeline at the ATS 2018 International Congress, 18-23 May in San Diego, US. The breadth and depth of science are reflected in the 60 accepted abstracts, including five oral presentations, which focus on key areas of unmet need in asthma and COPD.
AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
Pressmeddelanden • Maj 11, 2018 08:01 CEST
Lynparza tablets receive EU approval for the treatment of platinum-sensitive relapsed ovarian cancer
Pressmeddelanden • Maj 08, 2018 12:23 CEST
AstraZeneca and Merck & Co., Inc. today announced that the EMA has approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy, regardless of BRCA status.
AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets
Pressmeddelanden • Maj 07, 2018 15:07 CEST
AstraZeneca has entered into an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international markets.
Tagrisso receives positive EU CHMP opinion for 1st-line treatment of EGFR-mutated non-small cell lung cancer
Pressmeddelanden • Apr 27, 2018 13:32 CEST
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending a change to the terms of the Marketing Authorisation for Tagrisso to include the 1st-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
Ny studie: Patienter med svår astma träffar sällan en läkare trots att varannan patient har en okontrollerad sjukdom
Pressmeddelanden • Apr 27, 2018 08:09 CEST
Inför Världsastmadagen 1 maj: I PACEHR-studien har fler än 18,500 astmapatienter i Sverige studerats. Majoriteten hade en lindrig och medelsvår astma och 790 personer hade svår astma. Data från 36 vårdcentraler runt om i Sverige jämfördes med uppgifter från hälsoregister under åren 2006-2013. Syftet med studien var att beskriva förekomst, samsjuklighet, dödlighet och behandling av svår astma.
Pressmeddelanden • Apr 24, 2018 08:04 CEST
AstraZeneca and MedImmune, its global biologics research and development arm, today announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least two prior treatments.
Pressmeddelanden • Apr 19, 2018 08:01 CEST
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, (exon 19 deletions or exon 21 L858R mutations), as detected by an FDA-approved test.